Abstract: Crystalline forms of emetine dihydrochloride (Compound I dihydrochloride) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms of Compound I dihydrochloride.
Abstract: The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.
Type:
Grant
Filed:
January 17, 2020
Date of Patent:
September 6, 2022
Assignee:
Acer Therapeutics Inc.
Inventors:
Leah E. Appel, Joshua R. Shockey, D. Christopher Schelling
Abstract: The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
October 26, 2021
Assignee:
Acer Therapeutics Inc.
Inventors:
Leah E. Appel, Joshua R. Shockey, D. Christopher Schelling
© 2024 Justia
